Vaxcyte News and Activities
Presence
Vaxcyte develops vaccines for bacterial infectious diseases. Its main products are vaccine candidates and research services for healthcare providers, public health programs, and patients who need better disease prevention.
Vaxcyte products and services overview:
- Vaccine candidates
- Pneumococcal vaccines
- Shingles vaccines
- Research services
Revenue: ~$0 million
Employees: 300
Headquarters: San Carlos, United States (USA)
Vaxcyte is one of the...
Vaxcyte is a company listed under the stock ticker PCVX (US).
Executives
View the org chart displaying its 45 main executives
Most searched biographies at Vaxcyte
- Grant Pickering, President, Chief Executive Officer and Director
- Peter Hirth, Director
- Jacks Lee, Director
Popular executive movements at Vaxcyte
- Guy Hagen, who was Director, Clinical Quality Assurance, is promoted to Senior Director, Clinical Quality Assurance (posted on April 7 2026).
Create your alert
to follow the executive moves at Vaxcyte.
Biotechnology
Vaxcyte has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by Vaxcyte
- Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Vaxcyte, Inc.
- Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Vaxcyte, Inc.
- Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Vaxcyte, Inc.
- Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate - Vaxcyte, Inc.
- Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Vaxcyte, Inc.
- Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - Vaxcyte, Inc.
- Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Vaxcyte, Inc.
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc.
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - Vaxcyte, Inc.
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants - Vaxcyte, Inc.
- View more press releases Close
Social media about Vaxcyte
- Vaxcyte on Wikipedia, Google News & Yahoo Finance
- Vaxcyte on LinkedIn, X (Twitter) & YouTube
